Arcus Biosciences
RCUS
92 hedge funds and large institutions have $375M invested in Arcus Biosciences in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 26 increasing their positions, 26 reducing their positions, and 8 closing their positions.
225% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 8
37% more capital invested
Capital invested by funds: $274M → $375M (+$101M)
23% more funds holding
Funds holding: 75 → 92 (+17)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 26
0.38% less ownership
Funds ownership: 59.1% → 58.72% (-0.38%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $8K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$17.6M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$10.1M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$5.66M |
| 4 |
Millennium Management
New York
|
+$3.77M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$3.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$44M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.44M |
| 3 |
Janus Henderson Group
London,
|
-$2.99M |
| 4 |
BlackRock
New York
|
-$2.84M |
| 5 |
JP Morgan Chase
New York
|
-$999K |
RCUS Hedge Fund Activity: Q1 2020 in Review
92 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q1 2020, worth a combined $375M — up 37% from $274M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new RCUS positions and 8 closed out — a net gain of 18 holders — while 26 added to existing stakes and 26 trimmed.
The largest buyer was Boxer Capital, adding an estimated $17.6M. The largest seller was BVF Inc, cutting an estimated $44M.
- 92 institutional investors held Arcus Biosciences (RCUS) as of Q1 2020, up from 75 in Q4 2019.
- Funds reported $375M of Arcus Biosciences stock for Q1 2020, up 37% quarter-over-quarter.
- 26 funds opened new Arcus Biosciences positions in Q1 2020 and 8 closed out, a net change of +18 holders.
- The largest Arcus Biosciences buyer in Q1 2020 was Boxer Capital, an estimated $17.6M added.
- The largest Arcus Biosciences seller in Q1 2020 was BVF Inc, an estimated $44M sold.
Based on aggregated 13F filings for Q1 2020.